ISIS-2503

Description

ISIS-2503 is an experimental medication being studied for its potential use in treating metastatic or locally recurrent colorectal cancer. It is an antisense inhibitor, meaning it works by targeting the instructions (RNA) that cells use to make a specific protein. In this case, it targets H-ras, a protein involved in cell growth and division. The goal of this drug is to reduce the activity of the H-ras protein, potentially slowing down or stopping the growth of cancer cells. This drug is administered intravenously (IV) in cycles. It is currently in Phase 2 clinical trials, meaning it has shown some promise in earlier studies and is being tested in a larger group of patients to evaluate its effectiveness and side effects further. It is not yet approved for use in colorectal cancer.

Mechanism of Action

ISIS-2503 is an antisense inhibitor. It works by binding to a specific type of molecule called messenger RNA (mRNA). This mRNA carries instructions from DNA to make proteins. ISIS-2503 specifically targets the mRNA that codes for the H-ras protein. By binding to this mRNA, ISIS-2503 prevents the cell from making the H-ras protein. H-ras is a protein involved in signaling pathways that control cell growth and division. By reducing the amount of H-ras protein, ISIS-2503 aims to inhibit these pathways and potentially slow down the growth of cancer cells.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials